Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases

Psoriasis and hidradenitis suppurativa are often associated with obesity. Because chronic low-grade inflammation underlies these 2 diseases, they can progress to more severe forms in patients with obesity if weight-reduction measures are not taken. This review covers pharmacologic alternatives for t...

Descripción completa

Detalles Bibliográficos
Autores: Vilarrasa, Eva, Nicolau, Joana, Cueva, Pablo de la, Goday Arnó, Albert, Gallardo Hernández, Fernando, Martorell, Antonio, Carrascosa Carrillo, José Manuel
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/59888
Acceso en línea:http://hdl.handle.net/10230/59888
http://dx.doi.org/10.1016/j.ad.2023.10.019
Access Level:acceso abierto
Palabra clave:Psoriasis
Hidradenitis suppurativa
Obesity
Glucagon-like peptide-1 (GLP-1) agonists
Liraglutide
Semaglutide
id ES_c73cbdaa7f1a0bbca925a1e4c09a38ee
oai_identifier_str oai:recercat.cat:10230/59888
network_acronym_str ES
network_name_str España
repository_id_str
spelling Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseasesVilarrasa, EvaNicolau, JoanaCueva, Pablo de laGoday Arnó, AlbertGallardo Hernández, FernandoMartorell, AntonioCarrascosa Carrillo, José ManuelPsoriasisHidradenitis suppurativaObesityGlucagon-like peptide-1 (GLP-1) agonistsLiraglutideSemaglutidePsoriasis and hidradenitis suppurativa are often associated with obesity. Because chronic low-grade inflammation underlies these 2 diseases, they can progress to more severe forms in patients with obesity if weight-reduction measures are not taken. This review covers pharmacologic alternatives for treating obesity, with emphasis on the benefits associated with the novel use of glucagon-like peptide-1 (GLP-1) agonists that act on satiety receptors. These drugs have led to greater weight loss in clinical trials and real-world settings than orlistat, which until recently was the only drug approved for treating obesity in the European Union. Although experience with GLP-1 agonists in patients with obesity and inflammatory skin diseases is currently scarce, the promising results reported suggest they may offer a useful tool for managing obesity.Elsevier202420242024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/59888http://dx.doi.org/10.1016/j.ad.2023.10.019reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésActas Dermosifiliogr. 2024 Jan;115(1):T56-T65© 2023 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/598882026-05-29T05:05:01Z
dc.title.none.fl_str_mv Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases
title Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases
spellingShingle Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases
Vilarrasa, Eva
Psoriasis
Hidradenitis suppurativa
Obesity
Glucagon-like peptide-1 (GLP-1) agonists
Liraglutide
Semaglutide
title_short Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases
title_full Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases
title_fullStr Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases
title_full_unstemmed Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases
title_sort Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases
dc.creator.none.fl_str_mv Vilarrasa, Eva
Nicolau, Joana
Cueva, Pablo de la
Goday Arnó, Albert
Gallardo Hernández, Fernando
Martorell, Antonio
Carrascosa Carrillo, José Manuel
author Vilarrasa, Eva
author_facet Vilarrasa, Eva
Nicolau, Joana
Cueva, Pablo de la
Goday Arnó, Albert
Gallardo Hernández, Fernando
Martorell, Antonio
Carrascosa Carrillo, José Manuel
author_role author
author2 Nicolau, Joana
Cueva, Pablo de la
Goday Arnó, Albert
Gallardo Hernández, Fernando
Martorell, Antonio
Carrascosa Carrillo, José Manuel
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Psoriasis
Hidradenitis suppurativa
Obesity
Glucagon-like peptide-1 (GLP-1) agonists
Liraglutide
Semaglutide
topic Psoriasis
Hidradenitis suppurativa
Obesity
Glucagon-like peptide-1 (GLP-1) agonists
Liraglutide
Semaglutide
description Psoriasis and hidradenitis suppurativa are often associated with obesity. Because chronic low-grade inflammation underlies these 2 diseases, they can progress to more severe forms in patients with obesity if weight-reduction measures are not taken. This review covers pharmacologic alternatives for treating obesity, with emphasis on the benefits associated with the novel use of glucagon-like peptide-1 (GLP-1) agonists that act on satiety receptors. These drugs have led to greater weight loss in clinical trials and real-world settings than orlistat, which until recently was the only drug approved for treating obesity in the European Union. Although experience with GLP-1 agonists in patients with obesity and inflammatory skin diseases is currently scarce, the promising results reported suggest they may offer a useful tool for managing obesity.
publishDate 2024
dc.date.none.fl_str_mv 2024
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/59888
http://dx.doi.org/10.1016/j.ad.2023.10.019
url http://hdl.handle.net/10230/59888
http://dx.doi.org/10.1016/j.ad.2023.10.019
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Actas Dermosifiliogr. 2024 Jan;115(1):T56-T65
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419139907452928
score 15.81155

Similares en LA Referencia